Research advances in cancer therapy of cisplatin liposome
10.6039/j.issn.1001-0408.2025.03.17
- VernacularTitle:顺铂脂质体在肿瘤治疗中的研究进展
- Author:
Weixuan ZHAO
1
;
Xue LU
;
Ruilin ZHAO
;
Yanmei ZHANG
;
Ye YANG
;
Deying CAO
Author Information
1. 北京市科学技术研究院新材料与先进制造研究所,北京 100089
- Publication Type:Journal Article
- Keywords:
cisplatin;
liposome;
tumor;
co-delivery liposome;
stimuli-responsive liposome;
targeting liposome
- From:
China Pharmacy
2025;36(3):356-361
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy based on cisplatin or its combination therapy is a common cancer treatment method.However,the non-specific side effects of cisplatin,poor pharmacokinetic properties of small molecule drugs,and susceptibility to drug resistance greatly limit the clinical application of cisplatin as first-line anti-tumor drug.With the development of nanocarrier technology,liposomes have become an ideal carrier for delivering cisplatin drugs due to their excellent properties of targeting,reducing toxicity,and enhancing efficacy.This paper reviews the status of cisplatin liposome both domestically and internationally which have entered clinical trials,including L-NDDP,SPI-077?,Lipoplatin?,LiPlaCis,SLIT and 1LC,etc.Currently,only Lipoplatin? and ILC are showing good potential in cancer therapy.Although cisplatin liposome has made some progress in reducing systemic toxicity and improving treatment efficiency in clinical research,there is still potential for further improvement in tumor targeting and reducing side effects.In the future,more low-toxicity and efficient cisplatin liposomes can be developed through formulation technologies such as co-delivery liposome,stimuli-responsive liposome and targeting liposome.
